ADMA Biologics Faces Securities Fraud Lawsuit After Channel Stuffing Claims
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, are facing a class action lawsuit following allegations of revenue manipulation and undisclosed transactions. The legal action centers on claims that the company inflated its financial performance through aggressive distribution tactics and inadequate internal controls.
The lawsuit, filed in the United States District Court for the District of New Jersey under the caption Mazzarino v. ADMA Biologics, Inc., follows a critical report by Culper Research. The report alleged that ADMA engaged in "channel stuffing" by inducing distributors to stock excess product through rebates and extended payment terms, effectively booking revenue for sales that did not reflect actual market demand.
According to the complaint, ADMA Biologics failed to disclose these practices and maintained an undisclosed related party transaction, which led to misleading statements regarding the firm's growth and financial health. The impact on shareholders was significant: following the publication of the research report, ADMA stock dropped 29.1% over two trading days, closing at $9.63 per share on March 25, 2026. Investors seeking to serve as lead plaintiff in the class action have until August 10, 2026, to file their petitions with the court.
Comments (0)
No comments yet. Be the first!